DUR Committee
September 16, 2011 Minutes

Members Present
Robert Carlson, M.D.
William McCormick, Pharm.D. (telephonic)
John Pappenheim, M.D.
Mary-Beth Gardner, ANP
Chad Hope, Pharm.D. (DHSS)
Julie Pritchard, Pharm.D. (Magellan)

Members Absent
Dharna Begich, Pharm.D.
Jeff Demain, M.D.

- Previous and upcoming staffing changes were relayed to the committee by Chad Hope.
- The annual report was prepared and submitted by Chad Hope to CMS for FFY 2010. Discussion about the new reporting format occurred.
- Prospective DUR
    - Advair and LABA: It was decided that letters should be sent to prescribers if the doses of LABA prescribed exceeded the daily recommended dose. Quantity limits could be considered at a later time if the intervention letters were ineffective.
    - Lovaza: After brief discussion the committee unanimously approved a prior authorization requirement for Lovaza with grandfathering for recipients compliantly taking the medication during the last 6 months.
    - Niacin/AIM-HIGH: After lengthy discussion it was decided that no intervention should be made at this time as the study has not been published and this is a small issue relative to claim volume or cost for the program. The committee decided that a list of potential interventions more relevant to the program should be discussed at a later meeting.
    - New Prescription Medications: Chad Hope presented the Department's recommendations for products currently under the new prescription medication prior authorization and reached 6 months on the list. The recommendations were adopted unanimously.
    - Julie Pritchard engaged the group in discussion of prospective DUR claims processing edits and provided a background on what Alaska is currently using. Discussion regarding new Pro-DUR edits is to be held at the next meeting.
- Break
- Retrospective DUR
    - The profiles were discussed and intervention letters were generated based on the committee's recommendations.
- The meeting adjourned at 4:05 p.m.